Latest From Allozyne Inc.
BioNotebook: Merck drops Ariad's ridaforolimus; United Therapeutics, Infinity, Verastem updates; Dipexium, Achaogen IPO terms
Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaogen set IPO terms.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.
The next generation of antibody-drug conjugates have much room for improvement: engineered proteins, drugs, the linkers that bond them together, and perhaps even new targets to attack. All their complexity is an invitation to innovation, but will the parts come together into products that prove safe and efficacious in the clinic?
Poniard Pharmaceuticals, which is hoping to provide a way out for shareholders and complete a merger with privately held Allozyne before the end of 2011, has granted an undisclosed party the worldwide rights to its focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Allozyne Inc.
- Senior Management
Meenu Chhabra, Pres. & CEO
Kenneth Grabstein, PhD, CSO
- Contact Info
Phone: (206) 518-5700
1600 Fairview Ave. E
Seattle, WA 98102
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.